Teriparatide
Osteoporosis in selected high-risk patients
Evidence: Strong FDA-reviewed clinical evidence
Administration: Daily injection
Score 8.6/10Read Review →Evidence and regulatory context for peptide-based treatments connected to bone health.
Abaloparatide
Osteoporosis in selected high-risk patients
Evidence: Strong FDA-reviewed clinical evidence
Administration: Daily injection
Score 8.3/10Read Review →Established / approved options
Teriparatide and abaloparatide are FDA-approved for specific osteoporosis populations at high risk for fracture.
Being researched
MOTS-C interest remains investigational and is not an approved osteoporosis treatment.
How to use this page
Established options appear before experimental compounds. Goal relevance never overrides regulatory status or evidence quality.
Next step
Open the relevant treatment review for sources, risks, contraindications, and evidence gaps.
MyPeptideQuest
Information only. Not medical advice. No dosing or self-treatment instructions are provided.